Kronos Bio Corp (KRON): Price-to-Revenue Ratio
Kronos Bio, Inc. (KRON) leads in the development of small molecules to combat oncogenic factors, as confirmed by the median P/S. The 5.90 mark captures this metric. Risks are associated with strict ESG controls over laboratory emissions and energy consumption. Business stability relies on retaining leading biologists through stock options and the targeted hiring of clinical research experts.
Kronos Bio Corp (KRON) - metric breakdowns and financial figures
- current quotes and average value forecast:
- stock exchange capitalization data:
- issuer book value statistics:
- issuer credit burden and liquidity indicators:
Debt to Capital Kronos Bio, Inc.|KRON - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Kronos Bio Corporation|KRON - Company Total Debt|Debt to Book Capital Kronos Bio Corp|KRON - Company Long-Term Debts|Company Short-Term Loans and Borrowings Kronos Bio|Immediate Liquidity kronosbio.com
- earnings and multiples data:
KRON - Company Net Income|Expected Net Income Kronos Bio, Inc.|KRON - P/E Multiple|Forward P/E Multiple Kronos Bio Inc|KRON - Price/Earnings to Growth Ratio|Company Value to Operating Income Before Depreciation Ratio Kronos Bio Corp|KRON - Operating profit before deduction of amortization|Net earnings per one share for the last twelve months Kronos Bio|KRON - Earnings per share for the last twelve months|Quarterly EPS earnings growth kronosbio.com|KRON - Earnings per share growth in current year|Expected earnings per share trend next year Kronos Bio, Inc.
- issuer revenue and sales details:
Summary company analytics:kronosbio.com
Optimizing raw material supplies for anti-tumor research ensures Kronos Bio, Inc. (KRON) a stable operating cycle. The current price-to-sales multiple of 5.90 reflects the market valuation of each unit of sales; a sharp increase in this index may indicate the asset is overbought, while undervalued figures often signal hidden fundamental business risks.
Competing companies
INCY - Price to Sales|Price-to-Revenue Ratio HUTCHMED HCM|Nuvation Bio Inc - Price-to-Revenue Ratio|DAWN - Price-to-Revenue Ratio|Price to Sales Monopar Corp|INBX: P/S Multiple|Price-to-Revenue Multiple I-Mab Biopharma IMAB|Market Cap to Revenue FENC|Price to Sales Heron Therapeutics Inc HRTX|Market Cap to Revenue NVCT (Nuvectis)|CHRS (Coherus BioSciences, Inc) - Market Capitalization-to-Revenue Ratio|Corbus Pharmaceuticals - Market Cap to Revenue|Market Cap to Sales Volume CRDF (Cardiff Oncology Inc.)|BeyondSpring - P/S Multiple|Market Capitalization-to-Revenue Ratio BCAB (BioAtla, Inc.)|LIXT: P/S Multiple|Price to Sales Citius Pharmaceuticals, Inc. (CTXR)|Price-to-Revenue Ratio Cellectar Biosciences|BLRX: Market Capitalization-to-Revenue Ratio|P/S Multiple CANF|P/S Multiple aprea.com (APRE)|Price-to-Revenue Ratio Kazia Therapeutics Limited KZIA|SLXN (Silexion Therapeutics Corp.) - Price-to-Sales Ratio|NCNA: Market Cap to Revenue|Price to Sales chimerix.com|Cyclacel (CYCC) - Price-to-Revenue Ratio|G1 Therapeutics (GTHX) - P/S Multiple|Price-to-Revenue Ratio Kintara|ONCT: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Portage Biotech Inc. (PRTG)
